Egg Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Egg Allergy Market Outlook

Thelansis’s “Egg Allergy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Egg Allergy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Egg Allergy Overview

Egg allergy is an immune system response triggered by proteins in eggs, encompassing IgE antibody-mediated reactions and other allergies like atopic dermatitis and eosinophilic esophagitis. These involve a combination of IgE and cell-mediated mechanisms. The primary form, IgE-mediated or type I food allergy, constitutes most of the egg-related allergic responses and is distinguished by specific IgE antibodies targeted at allergens. Researchers have identified five major allergenic proteins in chicken eggs, labeled as Gal d 1-5. These proteins are primarily located in egg whites, with notable ones being ovomucoid (Gal d 1, 11%), ovalbumin (Gal d 2, 54%), ovotransferrin (Gal d 3, 12%), and lysozyme (Gal d 4, 3.4%). While ovalbumin (OVA) is the most abundant egg white protein, ovomucoid (OVM) has emerged as the predominant allergen. Egg allergy typically emerges during the latter part of a child's first year, with an average onset age of 10 months. Ranking second after cow's milk allergy, egg allergy is the second most prevalent food allergy in infants and young children. The management of egg allergy closely resembles other food allergies, necessitating education on avoidance strategies and how to handle allergic reactions if accidental exposure occurs. Eggs play a versatile culinary role across various cultures, contributing to a wide array of processed food items, challenging dietary egg avoidance, and raising significant quality of life concerns. Regrettably, no current treatments can cure or sustain relief from food allergies.

• The prevalence of egg allergy stands at 0.9% among all children and 1.3% among children under five. Within the children with egg allergies group, 64.2% displayed tolerance to baked egg products, and 60.2% exhibited allergies to other foods. Interestingly, those tolerating baked egg products reported a notably higher quality of life.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: